Hepatitis C and interferon: fewer cases of liver cancer.

Data on the risk of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C participating in placebo-controlled trials of interferon have been published after 3 to 9 years of follow-up. Among patients with chronic hepatitis C and either fibrosis or cirrhosis, interferon greatly reduced the risk of hepatocellular carcinoma after 8 years or more, especially when viral load was below the limit of detection.

Citation

Hepatitis C and interferon: fewer cases of liver cancer. Prescrire international. 2013 Jul;22(140):191

Mesh Tags

Substances

PMID: 23951600

search → result